1. Insulin resistance influences central opioid activity in polycystic ovary syndrome 
Alison Berent-Spillson, Ph.D., Tiffany Love, Ph.D., Rodica Pop-Busui, M.D., Ph.D., MaryFran Sowers, Ph.D., Carol C. Persad, Ph.D., Kathryn P. Pennington, M.D., Aimee D. Eyvazaddeh, M.D., M.P.H., Vasantha Padmanabhan, Ph.D., Jon-Kar Zubieta, M.D., Ph.D., Yolanda R. Smith, M.D. 
Fertility and Sterility 
Volume 95, Issue 8, Pages (June 2011)
DOI: /j.fertnstert
Copyright © 2011 American Society for Reproductive Medicine Terms and Conditions

2. Figure 1
(A) Prior to metformin treatment, IR-PCOS patients differed from controls in body composition, testosterone, and measures of insulin resistance. Metabolic measures improved after treatment but did not reach statistical significance. (B) IR-PCOS patients had greater mu-opioid receptor availability in the nucleus accumbens/ventral pallidum and amygdala prior to metformin treatment and compared to controls, and receptor binding potential correlated with measures of insulin resistance. (PET image) In vivo mu-opioid receptor binding potential in PCOS patients before and after metformin treatment: PCOS patients have greater mu-opioid binding potential prior to 4 months of metformin treatment, bilaterally in the nucleus accumbens/ventral pallidum (left panel) and in the amygdala (right panel).
Fertility and Sterility  , DOI: ( /j.fertnstert )
Copyright © 2011 American Society for Reproductive Medicine Terms and Conditions